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Background: IL-17A and IL-17F are pro-inﬂammatory cytokines which induce the expression of several cytokines,
chemokines andmatrix metalloproteinases (MMPs) in target cells. IL-17 cytokines have recently attracted huge in-
terest due to their pathogenic role in diseases such as arthritis and inﬂammatory bowel disease although a role for
IL-17 cytokines in myocardial infarction (MI) has not previously been described.
Methods: In vivoMI was performed by coronary artery occlusion in the absence or presence of a neutralizing IL-17
antibody for blocking IL-17 actions in vivo. IL-17 signaling was also assessed in isolated primary cardiomyocytes by
Western blot, mRNA expression and immunostaining.
Results: Expression of IL-17A, IL-17F and the IL-17 receptor (IL-17RA)were all increased followingMI. Expression of
several IL-17 target genes, including Cxcl1, Cxcl2, IL-1β, iNOS and IL-6 was also upregulated following MI. In addi-
tion, IL-17A promoted the expression of Cxcl1 and IL-6 in isolated cardiomyocytes in aMAPK and PI(3)K-dependent
manner. IL-17A and ischaemia/reperfusion (I/R) injury were found to have an additive effect on Cxcl1 expression,
suggesting that IL-17 may enhance myocardial neutrophil recruitment during MI. Moreover, protein levels of
both IL-17R and IL-17A were enhanced following in vivo MI. Finally, blocking IL-17 signaling in vivo reduced the
levels of apoptotic cell death markers following in vivoMI.
Conclusions: These data imply that the expression of IL-17 cytokines and their receptor are elevated duringmyocar-
dial I/R injury and may play a fundamental role in post infarct inﬂammatory and apoptotic responses.
© 2011 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Following the onset of myocardial ischaemia/reperfusion (I/R) inju-
ry, local release of cytokines and chemokines leads to neutrophil and
macrophage recruitment into the infarct area to facilitate clearance of
dead cells and matrix debris. Within two weeks of the initial MI, the in-
ﬂammation eventually resolves, dead cardiac myocytes are replaced by
granulation tissue, wound healing ensues and ﬁbroblasts and endothe-
lial cells are recruited to aid in scar formation and ventricular remodel-
ing [1]. Thus inﬂammation following I/R is initially beneﬁcial, although,
if prolonged, it can lead to signiﬁcant cardiac damage. Therefore, anti-
inﬂammatory therapies represent an attractive target for prevention
of MI related pathology. However, initial clinical anti-inﬂammatory
strategies for MI have so far proved disappointing, and thus a greateranou).
r CC BY-NC-ND license.understanding of how the inﬂammatory process is coordinated during
MI is needed [2].
The IL-17 cytokine family consists of 6 members (IL-17A-F).
IL-17A and IL-17F share the greatest similarity, with 55% homology
at the amino acid level. The Il17a and Il17f genes are adjacent on
human chromosome 6 and mouse chromosome 1 and may undergo
co-ordinate regulation [3]. IL-17A and IL-17F can be secreted as
both disulﬁde-linked homodimeric and heterodimeric glycoproteins
and have been shown to be produced by T cells, activated monocytes,
ﬁbroblasts and neutrophils [4]. IL-17A and IL-17F promote the release
of the cytokines IL-6, TNF-α and IL-1β, and the chemokines Cxcl1
(KC/Groα), MCP-1 (Ccl2) and IL-8 from ﬁbroblasts, endothelial cells
and leukocytes and thus are considered to be pro-inﬂammatory [5–
7]. In addition IL-17A and IL-17F have been shown to synergise with
other cytokines such as IL-1β, IFN-γ and TNF-α to enhance proinﬂam-
matory responses [8].
IL-17A and IL-17F are produced by the Th17 lineage of CD4+ effec-
tor T cells, and Th17 cells, and by inference IL-17A and IL-17F, are
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multiple sclerosis [9–11]. Little is known about IL-17 regulation in
the cardiovascular system, although IL-17A appears to be necessary
for the onset of ﬁbrosis, remodelling and progression to dilated car-
diomyopathy in a mouse model of myocarditis [12]. IL-17 has also
been implicated in renal I/R injury [13], although the mechanisms
by which IL-17 contributes to these myocardial and non-myocardial
ischaemic pathologies have not been studied. Therefore, we have
studied expression of IL-17 and its consequences in both in vitro
and in vivo models of myocardial I/R, and show that expression of
both IL-17 and its receptors, together with downstream IL-17 targets,
is increased by I/R, and that IL-17 neutralisation reduces myocardial
cell death.
2. Materials and methods
This study was performed in accordance with the United Kingdom Home Ofﬁce Ani-
mals (Scientiﬁc Procedures) Act 1986. All reagents were obtained from Sigma-Aldrich
(Poole Dorset, UK) unless otherwise stated. Recombinant IL-17 was from Peprotech. Neu-
tralizing IL-17 (AF-421-NA) was from R & D Systems.
2.1. In vivo ischemia/reperfusion injury in the rat
The method of coronary artery occlusion and reperfusion in the anaesthetised rat
was performed as previously described [14]. Brieﬂy, male Wister rats (255–285 g)
were anaesthetised with thiopentone sodium (Intraval® 120 mg/kg i.p.). Anesthesia
was maintained by supplementary injections of thiopentone sodiumas required. The tra-
chea was cannulated and the animals were ventilated with a Harvard ventilator (inspira-
tory oxygen concentration: 30%; 70 strokes/min, tidal volume: 8–10 ml/kg). Body
temperature was maintained at 37±1 °C and the right carotid artery was cannulated
and connected to a pressure transducer (Senso-Nor 840, Senso-Nor, Horten, Norway).
The right jugular veinwas then cannulated for the administration of drugs. A para-sternal
thoracotomy was then performed, using an electrosurgery device to cauterize the inter-
costal arteries before cutting through three ribs. The chest was retracted and pericardium
dissected from the heart. The left anterior descending (LAD) coronary artery was isolated
and a snare occluderwas placed around the LAD. The retractor was then removed and the
animal allowed to stabilise for 15 min. The occluder was tightened at time 0. After 25 min
of LAD-occlusion, the occluder was released to allow reperfusion for 2 h. At the end of the
reperfusion period, the LAD was re-occluded and 1 ml of Evans Blue dye (2% w/v) was
injected into the animal via the jugular vein. Evans Blue dye stains the tissue through
which it is able to circulate, so that the non-perfused vascular (occluded) tissue remains
uncoloured. Each animal was sacriﬁced with an over-dose of anaesthetic, the heart ex-
cised, and washed thoroughly in PBS. The heart was then sectioned into slices of 3–
4 mm, the right ventricle wall was removed, and the risk area (the non-perfused and,
hence, non-stainedmyocardium)was separated from the non-ischaemic (blue) tissue be-
fore being immediately snap-frozen in liquid nitrogen or ﬁxed in formaldehyde 4% for up
to 48 h.
2.2. In vivo neutralization of IL-17A
In a different set of experiments rats were treated with 200 μg of anti-IL-17A poly-
clonal antibody intraperitoneally (R & D Systems, AF-421-NA) or PBS 2 h before under-
going in vivo ischemia/reperfusion injury.
2.3. Assay of creatine phosphokinase
1 ml of blood was collected from the tail vein of sham operated rats, after thoracot-
omy, as well as control ischaemia/reperfusion and treated rats, at the end of theTable 1
Primers sequences used for qPCR analysis.
Gene Forward
IL-1β TTCAGGCAGGCAGTATCACT
inos AGCGGCTCCATGACTCTCA
Cxcl1 TCGCCAATGAGCTGCGCTGT
Mmp9 GAAGACGACATAAAAGGCATCC
IL-6 ACTGCCTTCCCTACTTCACA
Socs3 TGGTCACCCACAGCAAGTTT
IL-17A AGGCCCTCAGACTACCTCA
IL-17RA GGGTGTATGGCCTCATCAC
IL-17 F GGAGGATAACAGTGTGAGAG
MCP-1 TGCAGTTAATGCCCCACTCA
β2-microglobulin GTCTTTCTGGTGCTTGTCTCA
Hprt CTCATGGACTGATTATGGACAGGAC
β-actin AGATGACCCAGATCATGTTTGAGreperfusion time. CPK levels were evaluated spectrophotometrically, as previously de-
scribed [15].
2.4. Neonatal rat ventricular cardiac myocyte culture
Neonatal rat ventricular cardiac myocytes (NRVM) were isolated from the hearts of
1–3 day old Sprague Dawley rats. Hearts were removed and placed in oxygenated ADS
buffer (116 mM NaCl, 5.4 mM KCl, 20 mM HEPES, 0.8 mM NaH2PO4, 405.7 μM MgSO4,
5.5 mMglucose, pH 7.35). Heart tissue was digested in 10 ml oxygenated ADS buffer sup-
plemented with 0.1% collagenase and 0.025% pancreatin for 15 min. Liberated cells were
pelleted at 300 g for 5 min and resuspended in FBS. This digestion procedurewas repeated
7 times after which cells were plated at 37 °C for 1 h to allow adherence of ﬁbroblasts.
Myocytes were plated at a density of 2.5×105/ml in DMEM with 40 units/ml penicillin
(Gibco), 40 μg/ml streptomycin and 15% FBS. Cells were allowed to attach overnight and
the media was replaced with DMEM 1% FBS. For ischaemia/reperfusion experiments,
cells were incubated for 4 h in ischaemic buffer (137 mM NaCl, 12 mM KCL, 0.49 mM
MgCl2, 0.9 mM CaCl2, 4 mM HEPES, 20 mM sodium lactate, 10 mM deoxyglucose, pH
6.2) in a 37 °C hypoxic chamber with 5% CO2, 95% argon. Following hypoxia, medium
was replaced with DMEM 1% FBS and cells were reoxygenated in 5% CO2 in a 37 °C incu-
bator for 4 h. For experimental controls, cells were incubated for four hours in control
buffer (137 mM NaCl, 3.8 mM KCl, 0.49 mM MgCl2, 0.9 mM CaCl2, 4 mM HEPES, 10 mM
glucose, pH 7.4) then in DMEM 1% FBS.
2.5. Adenoviral infections
The STAT3C adenovirus was a kind gift from Prof. Michitaka Ozaki, Okayama Uni-
versity, Japan and the GFP adenovirus was a kind gift from Prof. Brian Foxwell, Imperial
College London, UK. Recombinant viruses were propagated using human embryonic
kidney 293 cells and puriﬁed through a cesium chloride gradient and PD-10 column
(GE Healthcare). Viral titre was determined by plaque assay in 293 cells. Viral trans-
duction was carried out by incubating cells at the indicated multiplicity of infection
(MOI) of 100 in serum free medium; after 2 h cells were washed and fresh media
added.
2.6. Affymetrix microarray analysis
RNA was extracted from the area at risk of the left ventricle using Trizol (Invitro-
gen). Biotinylated cRNA targets were prepared using the Ambion Message Amp II
protocol. 15 μg fragmented cRNA probes were added to 50 pM of control oligonucle-
otides (bioB, bioC, bioD and Cre), 30 μg herring sperm DNA, 150 μg BSA, 30 μl DMSO
and 150 μl hybridisation buffer to a ﬁnal volume of 300 μl, which was then heated
to 99 °C for 5 min then 45 °C for 5 min. 200 μl hybridisation mix was added to prehy-
bridised Affymetrix rat expression 230A microarrays and rotated overnight at
60 rpm for 16 h at 45 °C. Arrays were stained and washed on an Affymetrix GeneChip
Fluidics Station 450 using the standard Affymetrix EukGE-WS2v4 script and were
scanned using an Affymetrix GeneChip scanner. Scanned images were obtained
using Affymetrix GeneChip Operating Software (GCOS) and all microarrays passed
quality control standards which included present calls ≥40%, scaling factor b2,
GAPDH 3′/5′ ratios b3 and RNA degradation plots which showed equivalent slopes
between microarrays. Downstream analysis was conducted using the Bioconductor
R 2.8 programmes AffylmGUI [16] and OneChannelGUI [17]. Background correction,
normalisation and summarisation of the probe-level data into probe-set expression
values were carried out using GC-Robust Multi-array Analysis (GC-RMA) from
imported Affymetrix image (CEL) ﬁles. Differential expression was calculated based
on the Linear Models for Microarray (limma) statistics package in Bioconductor R
and multiple testing was corrected by using the Benjaminini and Hochberg false dis-
covery rate (FDR) [18]. Genes were considered to be differentially expressed where
there was a fold change ≥2 with an FDR-adjusted P value≤0.05. Each transcript
was annotated based on the gene identiﬁers present in the Affymetrix NetAffx data-
base. Microarray data has been deposited at the EMBL-EBI ArrayExpress repositoryReverse Accession number
CAGCATCTCGACAAGAGCTT NM_031512
TGCACCCAAACACCAAGGT NM_012611
GGGACACCCTTTAGCATCTT NM_030845.1
TCAGAAGGACCAGCAGTAG NM_031055
GCTCTGAATGACTCTGGCTT NM_012589
ACCAGCTTGAGTACACAGTC NM_053565.1
TCTCAGGCTCCCTCTTCAG NM_001106897.1
ACAGGCAGTGATCAGGAACT NM_001107883.2
ATTTCTTGCTGGATGGGGAC NM_001015011.1
TCTCACTTGGTTCTGGTCCA NM_031530.1
GTGAGCCAGGATATAGAAAGA NM_012512
GCAGGTCAGCAAAGAACTTATAGCC NM_012583
AGGTCCAGACGCAGGATG NM_031144
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some data has been previously reported [31].
2.7. Quantitative Real-Time PCR (qPCR)
RNA was extracted using Trizol reagent according to the manufacturer's instruc-
tions (Invitrogen, Paisley, UK) and cDNA was prepared using Superscript II (Invitro-
gen). qPCR was carried out using Platinum SYBR Green (Invitrogen) on the DNA
Engine Opticon system (MJ Research, Waltham, MA). For PCR reactions, 5 μl SYBR
Green was added to 5 μl cDNA with 500 nM primers in a 20 μl reaction and the PCR
conditions were 95 °C for 3 min, followed by 45 cycles of 95 °C for 30 s, 60 °C for 30 s
and 72 °C for 30 s. A melt-curve was performed from 65 °C to 95 °C, reading every
0.3 °C with a 1 s hold between reads. Speciﬁc primers were designed with the aid of
CloneWorks and the Ensembl database and are listed in Table 1. Where possible,
primers were intron-spanning; for single-exon genes, a control cDNA reaction without
reverse transcriptase was included to conﬁrm the absence of genomic DNA and all PCR
reactions were visualised on agarose gels to ensure the presence of a single product.
HPRT, β-Actin and β2-microglobulin were used together as normalising genes for
each experiment. Both target and normalising gene PCR efﬁciency was ﬁrstly deter-
mined to ensure normalizing genes were acceptable; to test primer efﬁciency, qPCR
was carried out on a 2-fold dilution series from a pooled set of cDNA and the threshold
Ct value was plotted against the log cDNA dilution. Efﬁciency was then calculated using
the equation m=(−1/ logE), where m is the slope of the line and E is the efﬁciency,
and primer pairs were used only if the PCR efﬁciency of the normalising and control
genes were found to be within 10% of each other [19]. Expression changes were calcu-
lated using the 2−ΔΔCt method and expressed as fold change over control [20].A
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Fig. 1. IL-17A, IL-17F, IL-17 receptor and IL-17 target genes are transcriptionally upregulate
rats undergoing sham operation or 25 min ischaemia and 2 h reperfusion (I/R). (A) IL-17RA
levels were assessed by western blot, GAPDH was used as a loading control. (C) Expression2.8. Preparation and staining of sections
Serial 5-mmmyocardial sections were cut from parafﬁn blocks and, after dewaxing
and heat-mediated antigen retrieval, were stained with TUNEL reagents and propi-
dium iodide, as previously described [15]. Data are expressed as the means of 12–15
high power ﬁelds±SD.
2.9. Western blot
Cells were lysed in RIPA buffer (0.75 M NaCl, 5% (v/v) NP40, 2.5% (w/v) deoxycho-
late, 0.5% (w/v) SDS, 0.25 M Tris–HCl pH 8.0, 10 mM DTT containing protease inhibi-
tor cocktail) and centrifuged at 13,000×g to pellet cell debris. Protein concentration
from the supernatant was determined using the BCA protein assay kit (Pierce, Rock-
ford, USA). 20 μg of protein was electrophoresed on 10% polyacrylamide gels, trans-
ferred to Hybond-C nitrocellulose membranes (Amersham Biosciences, Bucks, UK)
and blocked for 30 min in 4% non-fat dry milk in TBS. Following protein transfer, ni-
trocellulose membranes were incubated overnight with the following antibodies:
STAT3, IL-17 and IL-17 receptor, pERKY204 and ERK were from Santa Cruz, GAPDH
was from Chemicon and pJNKT183/T185, JNK, pp38T180/Y182, p38, pAKTS473, AKT active
caspase 3 were from Cell Signaling. Secondary antibodies were from DAKO.
2.10. Statistical analysis
Statistical analysis was carried out using a Student's t-test or a one way ANOVA
with Dunnet's post test, p-values of less than 0.05 were considered signiﬁcant. Error
bars represent mean±SEM.Sham I/R
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d following in vivo I/R injury. RNA and protein was extracted from the left ventricles of
, IL-17A and IL-17F expression was measured by qPCR. (B) IL-17A and IL-17RA protein
of the IL-17 target genes IL-6, IL-1, iNOS and MMP-9 was measured by qPCR.
Table 2
Modulation of mRNA genes in the intact heart following in vivo I/R. Details of the Affymetyrix microarray analysis is described in the Materials and methods section.
AffyID Symbol Gene title FC P value
Cell migration
1387316_at Cxcl1 Chemokine (C-X-C motif) ligand 1 (KC) 5.00 4.6E−03
1368760_at Cxcl2 Chemokine (C-X-C motif) ligand 2 (MIP2a) 27.68 2.5E−03
1370634_x_at Cxcl3 Chemokine (C-X-C motif) ligand 2 (MIP2b) 4.14 5.2E−03
1367973_at Ccl2 Chemokine (C-C motif) ligand 2 (MCP-1) 5.08 2.4E−04
1370083_at Ccr1 Chemokine (C-C motif) receptor 1 7.21 1.7E−03
1387202_at Icam1 Intercellular adhesion molecule 1 4.30 1.3E−02
Inﬂammatory mediators
1398256_at Il1b Interleukin 1 beta 12.83 1.4E−03
1387667_at Nos2 Nitric oxide synthase 2, inducible 11.79 1.3E−02
1369191_at Il6 Interleukin 6 9.39 2.9E−03
1387011_at Lcn2 Lipocalin 2 3.95 2.5E−02
1368527_at Ptgs2 Prostaglandin-endoperoxide synthase 2 (Cox-2) 2.70 1.5E−02
1368494_at S100a8 S100 calcium binding protein A8 8.51 2.7E−03
1387125_at S100a9 S100 calcium binding protein A9 8.00 1.8E−04
Tissue remodelling
1398275_at Mmp9 Matrix metallopeptidase 9 10.22 3.2E−03
1367712_at Timp1 TIMP metallopeptidase inhibitor 1 6.36 2.2E−04
Other
1388596_at Cotl1 Coactosin-like 1 3.24 4.5E−03
1373554_at Spsb1 splA and SOCS box containing 1 3.10 6.9E−04
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3.1. Il-17 cytokines and their downstream effectors are upregulated in a
myocardial infarction model
To identify novel regulators of myocardial I/R injury, we carried
out microarray analysis of differentially expressed genes following
in vivo myocardial infarction in the rat. This model consisted of
25 min ischaemia and 2 h reperfusion resulting in an average infarct
size of 56.0±2.0%. Microarray analysis was performed on left ventric-
ular tissue isolated from the area at risk. Examination of differentially
expressed genes showed that the IL-17 receptor (IL-17RA) was upre-
gulated 7.0±1.1 fold and this was veriﬁed by qPCR (Fig. 1a). We also
examined the expression of IL-17A and IL-17 F by qPCR and found
that their expression was also upregulated 8.3±3.2 fold and 4.3±
1.3 fold respectively following I/R. In addition we examined the pro-
tein levels of IL-17RA and IL-17A and found a signiﬁcant increase in
both (Fig. 1b). We were also interested in whether downstream me-
diators of IL-17might be induced by I/R injury, and amanual search of
the microarray dataset revealed a number of known IL-17 targets
which were upregulated by I/R injury, including genes involved in
cell migration, inﬂammation and tissue remodeling (Table 2). The ex-
pression of several of these, including IL-1β, iNOS, IL-6 and MMP-9,
was veriﬁed by PCR (Fig. 1c), although it must be stressed that,
while these are indeed downstream targets of IL-17 signalling, they
can be induced by multiple stimuli in the ischaemic heart.3.2. IL-17 enhances I/R dependent Cxcl1 expression in cardiac myocytes
We next examined the expression of particular IL-17 targets in
cardiac myocytes in more detail. The chemokine Cxcl1 (KC) and its
receptor CXCR2 play a signiﬁcant role in neutrophil inﬁltration into
inﬂamed tissue [3]. We found that Cxcl1 was rapidly induced (within
1 h) in response to IL-17A and stayed elevated over a 24 h period, al-
beit with a decline between 6 h and 12 h (Fig. 2a). IL-6 also displayed
a biphasic regulation in response to IL-17A, with slightly increased
levels at 1 h, returning to baseline by 2 h and then increasing again
from 6 h on (Fig. 2b). IL-17A has previously been shown to induce ro-
bust MCP-1 (CCL2) expression in ﬁbroblasts, macrophages, epitheli-
um, mesangial cells, astrocytes and glial cells [21–23]. However wefound that IL-17 did not affect MCP-1 levels in cardiac myocytes sug-
gesting that cardiac myocytes respond to IL-17 in a cell type speciﬁc
manner (Fig. 2c). Since both IL-17 and IL-6 induce STAT3 activity,
we also examined the expression of the STAT3 target gene Socs3.
The expression pattern of Socs3 was found to closely parallel that of
IL-6 suggesting that changes in Socs3 expression may be secondary
to IL-6 production (Fig. 2d).
We next examined the effect of co-administration of IL-17 on
I/R-induced Cxcl1 expression. Both I/R injury and IL-17A increased
Cxcl1 levels, and treating myocytes with IL-17 at the time of reperfu-
sion resulted in an additive effect on I/R induced Cxcl1 expression
(Fig. 2e). This suggests that IL-17 production during I/R injury leads
to augmented expression of Cxcl1 which may enhance recruitment
of inﬂammatory cells into the heart.
3.3. IL-17A induces Cxcl1 and IL-6 expression in cardiac mycoytes in a
ERK1/2, p38 and PI(3)K dependent manner
Since IL-17A has been shown to regulate MAPKs in other cell
types, we examined the kinetics of MAPK activity in NRVMs following
IL-17A treatment, and found that IL-17A had differing kinetic effects
on each MAPK tested (Fig. 3a). ERK1/2 phosphorylation was induced
within 15 min of IL-17A stimulation and remained elevated up to
16 h. In contrast, JNK was rapidly phosphorylated which returned to
baseline by 1 h. p38 phosphorylation increased slightly upon IL-17A
treamtment and then was dephosphorylated from 1 h onwards. We
also examined Akt activity and found a similar kinetic proﬁle to JNK,
with rapid induction within the ﬁrst hour followed by dephosphory-
lation. Thus thekinetics of cardiacmyocyteMAPK activation in response
to IL-17 are highly dynamic.
Next we examined what contribution IL-17-mediated activation of
MAPKs and PI(3)K/Akt had on IL-17-dependent regulation of Cxcl1 and
IL-6 expression. Cardiac myocytes were pre-treated for 30 min with var-
ious inhibitors. IL-17 was then added to the culture medium for 6 h and
the expression of Cxcl1 and IL-6 assessed by qPCR. Inhibition of ERK1/2,
p38 or PI(3)K all signiﬁcantly reduced IL-17-mediated Cxcl1expression,
although only U0126 abolished expression completely; inhibition of JNK
or JAK2 had no effect (Fig. 3b). Likewise, IL-17 mediated IL-6 expression
was found to be dependent on ERK1/2, p38 and PI (3) K while inhibition
of JAK2 with AG490 slightly increased IL-6 expression but this did not
reach statistical signiﬁcance (Fig. 3b). Interestingly, inhibition of JNK
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Fig. 2. IL-17 induces Cxcl1, IL-6 and Socs3 expression in cardiac myocytes. Neonatal rat ventricular myocytes were treated with 10 ng/ml IL-17 for the indicated times and the levels
of (A) Cxcl1, (B) IL-6, (C) MCP-1 and (D) Socs3 were measured by qPCR. Experiments were repeated in duplicate, statistical analysis was carried out using a one-way ANOVA fol-
lowed by Dunnett's post test, *pb0.05, **pb0.01, ***pb0.001. (E) I/R injury and IL-17 have additive effects on Cxcl1 expression. NRVMs were subjected to 4 h ischaemia and 6 h
reperfusion with or without 10 ng/ml IL-17 which was added at the time of reperfusion. The expression of Cxcl1 was analysed by qPCR. Statistical analysis was carried out using
student's t-test. **pb0.01, **pb0.001.
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actually inhibit IL-17 dependent IL-6 expression, although it must be
noted that SP600125 has documented off-target effects [24]. These data
show that in cardiac myocytes, activation of ERK1/2, p38 and PI(3)K are
necessary for maximum induction of IL-17 dependent targets.
3.4. IL-17F and IL-17RA mRNA and protein levels are upregulated in
primary cardiac myocytes and also in the in vivo heart following ischemia/
reperfusion injury
In order to examine IL-17 regulation in cardiac cells,we subjectedneo-
natal cardiacmyocytes (NRVMs) to simulated I/R injury in vitro andmea-
sured the expression of IL-17RA, IL-17A and IL-17F by qPCR. The mRNA
expression of IL-17RA was time-dependently increased during I/R injury
in NRVMs, reaching a maximum of 2.3±0.4 fold increase over baseline
by 4 h (Fig. 4a). The mRNA expression of IL-17F was increased duringischaemia and reached a maximum of 32.3±4.4 fold by 4 h reperfusion
and remained elevated up to 24 h (Fig. 4a). Thus, in agreement with
data from the whole heart, both IL-17RA and IL-17F show increased ex-
pression in isolated cardiac myocytes shortly after the onset of reperfu-
sion. We veriﬁed these results by subjecting the rat myobast cell line
H9c2 to I/R injury. As in the NRVMs, we saw upregulation of IL-17F
mRNA levels by 4 h reperfusion (Fig. 4b). The expression of the IL-17 tar-
get gene Cxcl1 was also upregulated by 4 h reperfusion, although in con-
trast to NRVMs, IL-17RA levels did not increase upon reperfusion in H9c2
cells. Since oxidative stress represents a signiﬁcant component of I/R inju-
ry,we also examined the expressionof IL-17F and IL-17RA followingH2O2
treatment of NRVMs. Oxidative stress resulted in increased expression of
IL-17F and Cxcl1 did not affect levels of the IL-17 receptor (Fig. 4c). Taken
together, these data show that IL-17 signalling is augmented in cardiac
myocytes during I/R injury and suggests that these changes are, at least
in part, consequent on oxidative stress.
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We have previously shown that the STAT3 transcription factor is in-
ducedwithin 1 h of reperfusion in cardiacmyocytes [25].We noted that
I/R mediated expression of IL-17F displayed a similar kinetic proﬁle to
that of the STAT3 target gene SOCS3,withmaximal expression between
2 and 4 h, returning to lower levels by 24 h [25]. STAT3 has been shown
to bind to both the IL-17A and IL-17F promoters in CD4+ T cells, and
STAT3 deﬁcient T cells produce substantially less IL-17A and IL-17F
under TGFβ+IL-6 polarizing conditions [26]. This suggests that induc-
tion of STAT3 during I/R injury could be responsible for upregulation
of IL-17F mRNA levels in cardiac myocytes. To address this, we trans-
duced NRVMs with an adenovirus expressing a constitutively active
form of STAT3 (STAT3C) or a control GFP adenovirus. Transduction of
myocytes with STAT3C resulted in robust induction of STAT3 protein
and IL-17F mRNA, showing that IL-17F is indeed a target of STAT3 in
cardiac myocytes, and thus I/R dependent induction of IL-17 genes
may be STAT3 dependent (Fig. 4D).
3.6. Blocking IL-17 signaling reduces myocyte necrosis and apoptosis in
the rat heart exposed to in vivo ischaemia/reperfusion
Since IL-17 has been reported to be a target for therapeutic inter-
vention in immune and inﬂammatory diseases [11] and also in the
progression of dilated cardiomyopathy [12] we addressed whether
blocking IL-17 signaling is beneﬁcial in the intact heart followingI/R. As shown in Fig. 5A, I/R injury resulted in greatly elevated levels of
circulating CPK (971+64mU/min/GWW) which were reduced by over
50% in response to IL-17 inhibition, demonstrating signiﬁcantly reduced
myocardial necrosis. Moreover, animals injected intra-peritoneally (i.p)
with an IL-17 neutralizing antibody were found to have signiﬁcantly re-
duced myocardial apoptosis as assessed by TUNEL positivity (Fig. 5B)
and by reduced levels of cleaved caspase-3 in response to I/R (Fig. 5C).
Overall, these data suggest that the enhanced IL-17 signaling following
I/R injury may promote myocardial damage.
4. Discussion
In this study, we show that I/R injury in the heart enhances ex-
pression of IL-17RA and its cognate ligands, IL-17A and IL-17F. More-
over, this enhanced IL-17 signalling results in increased expression of
downstream pro-inﬂammatory targets, such as Cxcl1 and IL-6, which
is mediated by activation of a number of MAPKs. In the intact heart in
vivo, IL-17 neutralisation results in reduced necrotic and apoptotic
myocyte death, suggesting that inhibition of the IL-17 pathway may
be of therapeutic beneﬁt in human MI.
IL-17 is a proinﬂammatory cytokine which is involved in the
clearance of extracellular pathogens and has been implicated as a driv-
ing force in many inﬂammatory diseases. IL-17 has been demonstrated
to be instrumental in the progression to dilated cardiomyopathy in au-
toimmune myocarditis [12], although the precise role of the IL-17 fam-
ily in the myocardium remains poorly deﬁned. Elevated expression of
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332 S.P. Barry et al. / International Journal of Cardiology 163 (2013) 326–334the receptor IL-17RA has previously been detected in diseased tissue,
for example in the joints of arthritic patients and in the CNS ofmice dur-
ing autoimmune encephalomyelitis [27].
The IL-17-induced chemokine, Cxcl1, was originally isolated from
a cDNA screen of PDGF inducible genes and, like all CXC chemokines,
is strongly chemotactic for neutrophils due to the tripeptide ELR
(Gln-Leu-Arg) motif located between the N terminus and the ﬁrst
cysteine [7,8]. We found that IL-17A increased Cxcl1 expression incardiac myocytes and I/R injury augmented this response. The co-op-
erativity between reperfusion injury and IL-17A may be explained by
the increased levels of IL-17RAwhich are seen early in I/R injury. Thus
the heart responds to I/R injury by upregulating the IL-17 receptor
and this then primes the heart for further signals mediated by the in-
creased levels of IL-17A and IL-17F, thereby facilitating increased pro-
duction of chemokines. Another possible explanation lies in the fact
that IL-17A cooperates with cytokines such as TNF-α to stabilize
Fig. 5. Blocking IL-17 signalling with a speciﬁc anti-IL-17 neutralizing antibody reduced creatine phosphokinase and apoptotic cell death in the myocardium following in vivo I/R
injury. Plasma concentration of CPK (A) and apoptosis assessed by the TUNEL assay (B) in sham-operated (control) or rats exposed to in vivo I/R injury (I/R) or I/R plus treatment
with IL-17 neutralizing antibody (IL-17 Bo Ab). Immunoﬂuorescence data (left panel) (Data are mean of ±6 rats **Pb0.001). Anti-IL-17 neutralizing antibody also reduced the in-
crease in cleaved/active caspase-3 expression following in vivo I/R injury (C). Western blot analysis was performed on tissue lysates prepared as in Fig. 3A above and immunoblotted
with a speciﬁc antibody against the cleaved and active form of caspase-3 and GAPDH.
333S.P. Barry et al. / International Journal of Cardiology 163 (2013) 326–334mRNA transcripts [28]. Since TNF-α is known to be produced by car-
diac myocytes in response to I/R injury, IL-17 may work in partner-
ship with TNF-α to stabilize Cxcl1 mRNA levels in the infarcted
heart. We therefore suggest that increases in IL-17 dependent signal-
ling may serve as an important regulator of neutrophil migration into
the myocardium.
We found that isolated cardiac myocytes express very low mRNA
levels of IL-17A. However IL-17A has been shown to be produced by
cardiac ﬁbroblasts, and thus the increased expression seen in the
whole heart following MI may be of ﬁbroblast origin [28]. In contrast,
I/R injury or oxidative stress led to a robust induction of IL-17F mRNA
in NRVMs, suggesting that cardiac myocytes may exclusively express
this form of IL-17.While IL-17A and IL-17F can have both complemen-
tary and distinct functions, they also associate to form an IL-17A/F het-
erodimer which possesses intermediate levels of activity compared to
homodimers [3]. Therefore, cardiac myocyte derived IL-17F may asso-
ciate with IL-17A from other cellular sources within the heart.
STAT3 has been shown to be necessary for both the differentiation
and stabilization of Th17 cells via transactivation of the Th17 speciﬁc
transcription factors, retinoic acid receptor-related orphan receptor
gamma (RORγ) and alpha (RORα) [29]. Moreover, STAT3 is necessary
for the subsequent production of IL-17A and IL-17F which mediate
Th17 cells' biological effects. We have shown that the expression of
IL-17F during I/R injury in cardiac myocytes closely paralleled that
of STAT3 activity and that overexpression of STAT3 alone was sufﬁ-
cient to drive expression of IL-17F. The JAK/STAT pathway is a major
determinant of myocardial viability following I/R injury [30] and our
results suggest that it may also drive cardiac inﬂammation through
induction of IL-17F in cardiac myocytes.
Taken together, these data show that I/R injury is associated with
activation of the IL-17 pathway and its downstream targets in the
heart, and that this contributes to the necrotic and apoptotic loss of
end-stage cardiomyocytes. Elevated IL-17 signalling in turn promotesCxcl1 production in cardiac myocytes and thus may represent a major
mediator of neutrophil inﬁltration into the heart following MI. Our
present data also show that blocking IL-17 reduced the levels of apo-
ptotic cell death in the heart following I/R and suggests that targeting
IL-17 cytokines may be an effective strategy for MI. Further investiga-
tion into the clinical efﬁcacy of inhibiting IL-17 signalling in the heart
as a treatment option for early reperfusion injury is warranted
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